All In Biotech

Drug Trial Radar · NCT06911866

A Phase Ib Study of RC1416 Injection

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Efficacy of RC1416 Injection in Patients With Moderate to Severe Asthma

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Oct 25, 2024

Primary completion

Sep 25, 2025

Study completion Sep 25, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma.

Conditions

  • Moderate to Severe Asthma

Interventions

  • RC1416Drug

    there are four doses(200mg-400mg) in this part. Each subjects will receive the drug once by subcutaneous injection.

  • RC1416 PlaceboDrug

    Each subjects will receive the placebo once by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AETime frame: up to 141 days
  2. SAETime frame: up to 141 days
  3. Vital SignsTime frame: up to 141 days
  4. Laboratory TestsTime frame: up to 141 days
  5. ECGTime frame: up to 141 days
  6. Injection Site ReactionTime frame: up to 85 days

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

  • Peking University Shougang Hospital

    Beijing, Beijing Municipality, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

  • The First Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Hebei Petro China Centre Hospital

    Langfang, Hebei, China

  • Hebei Province Hospital of Chinese Medicine

    Shijiazhuang, Hebei, China

  • Nanyang Central Hospital

    Nanyang, Henan, China

  • Xinxiang First People's Hospital

    Xinxiang, Henan, China

  • The First Affiliated Hospital of Baotou Medical College

    Baotou, Inner Mongolia, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, China

  • Jining NO.1 people's hospital

    Jining, Shandong, China

  • Liaocheng People's Hospital

    Liaocheng, Shandong, China

  • Zibo Municipal Hospital

    Zibo, Shandong, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.